Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP-27, but not PACAP-38) degradation by the neutral endopeptidase EC 3.4.24.11

Biochemical Pharmacology

Volumn 54, Issue 4, 1997, Pages 509-515

  Gourlet, Philippe ^a   Vandermeers, André ^a   Robberecht, Patrick ^a,b   Deschodt Lanckman, Monique ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b Bât G E   (Belgium)

Author keywords

Degradation; Metabolite activity; Neutral endopeptidase; PACAP; VIP

Indexed keywords

DRUG METABOLITE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE 27; MEMBRANE METALLOENDOPEPTIDASE; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DEGRADATION; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION;

AMINO ACID SEQUENCE; HUMANS; KIDNEY; MOLECULAR SEQUENCE DATA; NEPRILYSIN; NEUROPEPTIDES; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0030884084     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00207-4     Document Type: Article

References (34)

1. Arimura A, Pituitary adenylate cyclase activating polypeptide (PACAP): Discovery and current status of research. Regul Pept 37: 287-303, 1992.
2. Sundler F, Ekblad E, Absood A, Håkanson R, Köves K and Arimura A, Pituitary adenylate cyclase-activating peptide: A novel vasoactive intestinal peptide-like neuropeptide in the gut. Neuroscience 46: 439-454, 1992.
3. Uddman R, Luts A, Arimura A and Sundler F, Pituitary adenylate cyclase-activating peptide (PACAP), a new vasoactive intestinal peptide (VIP)-like peptide in the respiratory tract. Cell Tissue Res 265: 197-201, 1991.
4. Christophe J, Type I receptors for PACAP (a neuropeptide even more important than VIP?). Biochim Biophys Acta 1154: 183-199, 1993.
5. Ishihara T, Shigemoto R, Mori K, Takahashi K and Nagata S, Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron 8: 811-819, 1992.
6. 2 receptor: Molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS Lett 334: 3-8, 1993.
7. Usdin TB, Bonner TI and Mezey E, Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology 135: 2662-2680, 1994.
8. Krempels K, Usdin TB, Harta G and Mezey E, PACAP acts through VIP type 2 receptors in the rat testis. Neuropeptides 29: 315-320, 1995.
9. Robberecht P, Gourlet P, Vertongen P and Svoboda M, Characterization of the VIP receptor from SUP T1 lymphoblasts. Adv Neuroimmunol 6: 49-57, 1996.
10. Araki N and Tagaki K, Relaxant effect of pituitary adenylate cyclase-activating polypeptide on guinea-pig tracheal smooth muscle. Eur J Pharmacol 216: 113-117, 1992.
11. Linden A, Yoshihara S, Chan B and Nadel JA, Inhibition of bronchoconstriction by pituitary adenylate cyclase-activating polypeptide (PACAP 1-27) in guinea-pigs in vivo. Br J Pharmacol 115: 913-916, 1995.
12. Cardell LO, Uddman R, Luts A and Sundler F, Pituitary adenylate cyclase-activating peptide (PACAP) in guinea-pig lung: distribution and dilatory effects. Regul Pept 36: 379-390, 1991.
13. Foda HD, Sharaf HH, Absood A and Said SI, Pituitary adenylate cyclase-activating peptide (PACAP), a VIP-like peptide, has prolonged airway smooth muscle relaxant activity. Peptides 16: 1057-1061, 1995.
14. Roques BP, Noble F, Daugé V, Fournié-Zaluski MC and Beaumont A, Neutral endopeptidase 24.11: Structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev 45: 87-146, 1993.
15. Deschodt-Lanckman M, Pauwels S, Najdovski T, Dimaline R and Dockray GJ, In vitro and in vivo degradation of human gastrin by endopeptidase 24.11. Gastroenterology 94: 712-721, 1988.
16. Ciccarelli E, Svoboda M, De Neef P, Di Paolo E, Bollen A, Dubeaux C, Vilardaga JP, Waelbroeck M and Robberecht P, Pharmacological properties of two recombinant splice variants of the PACAP type I receptor transfected and stably expressed in CHO cells. Eur J Pharmacol 288: 259-267, 1995.
17. Ciccarelli E, Vilardaga JP, De Neef P, Di Paolo E, Waelbroeck M, Bollen A and Robberecht P, Properties of the VIP-PACAP type II receptor stably expressed in CHO cells. Reg Pept 54: 397-407, 1994.
18. Svoboda M, Tastenoy M, Van Rampelbergh J, Goossens JF, De Neef P, Waelbroeck M and Robberecht P, Molecular cloning and functional characterization of a human VIP receptor from SUP-T1 lymphoblasts. Biochem Biophys Res Commun 205: 1617-1624, 1994.
19. Tam EK and Caughey GH, Degradation of airway neuropeptides by human lung tryptase. Am J Respir Cell Mol Biol 3: 27-32, 1990.
20. Caughey GH, Leidig F, Viro NF and Nadel JA, Substance P and vasoactive intestinal peptide degradation by mast cell tryptase and chymase. J Pharmacol Exp Ther 244: 133-137, 1988.
21. Franconi GM, Graf PD, Lazarus SC, Nadel JA and Caughey GH, Mast cell tryptase and chymase reverse airway smooth muscle relaxation induced by vasoactive intestinal peptide in the ferret. J Pharmacol Exp Ther 248: 947-951, 1989.
22. Bolin DR, Michalewsky J, Wasserman MA and O'Donnell M, Design and development of a vasoactive intestinal peptide analog as a novel therapeutic for bronchial asthma. Biopolymers 37: 57-66, 1995.
23. Bernhard W, Bothe-Sandtfort E, Koop H, Cassel W and Von Wichert P, Degradation of vasoactive intestinal peptide by isolated, ventilated, and perfused rat lungs. Eur J Clin Invest 19: 506-513, 1989.
24. 2-terminal histidyl residue. Mol Cell Endocrinol 52: 97-103, 1987.
25. Kobayashi R, Chen Y, Lee TD, Davis MT, Ito O and Walsh JH, Degradation of vasoactive intestinal polypeptide by rabbit gastric smooth muscle membranes. Peptides 15: 323-332, 1994.
26. Suzuki H, Gao XP, Olopade CO and Rubinstein I, Neutral endopeptidase modulates VIP-induced vasodilation in hamster cheek pouch vessels in situ. Am J Physiol 271: R393-R397, 1996.
27. Borson DB, Roles of neutral endopeptidase in airways. Am J Physiol 260: L212-L225, 1991.
28. Baraniuk JN, Ohkubo K, Kwon OJ, Mak J, Rohde J, Kaliner MA, Durham SR and Barnes PJ, Identification of neutral endopeptidase mRNA in human nasal mucosa. J Appl Physiol 74: 272-279, 1993.
29. Goetzl EJ, Sreedharan SP, Turck CW, Bridenbaugh R and Malfroy B, Preferential cleavage of amino-and carboxyl-terminal oligopeptides from vasoactive intestinal polypeptide by human recombinant enkephalinase (neutral endopeptidase, EC 3.4.24.11). Biochem Biophys Res Commun 158: 850-854, 1989.
30. Beaumont A, Le Moual H, Boileau G, Crine P and Roques BP, Evidence that both arginine 102 and arginine 747 are involved in substrate binding to neutral endopeptidase (EC 3.4.24-11). J Biol Chem 266: 214-220, 1991.
31. Foda HD and Said Sl, Helodermin, a C-terminally extended VIP-like peptide, evokes long-lasting relaxation. Biomed Res 10: 107-110, 1989.
32. O'Donnell M, Garippa RJ, O'Neill NC, Bolin DR and Cottrell JM, Structure-activity studies of vasoactive intestinal polypeptide. J Biol Chem 266: 6389-6392, 1991.
33. Gourlet P, Vilardaga JP, De Neef P, Waelbroeck M, Vandermeers A and Robberecht P, The C-terminus ends of secretin and VIP interact with the N-terminal domains of their receptors. Peptides 17: 825-829, 1996.
34. 2 recombinant receptors. Regul Pept 62: 125-130, 1996.